Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Saikat Chaudhuri at CSIR-Central Leather Research Institute, India.

Assist. Prof. Dr. Saikat Chaudhuri is an accomplished organic chemist specializing in natural product synthesis and green chemistry. 🎓 He earned his Ph.D. from IISER Bhopal, focusing on Clavine alkaloids, and holds degrees from Visva Bharati and Burdwan Universities. 🏅 He is a recipient of the Young Scientist Award (2024) and prestigious UGC fellowships. At CSIR-CLRI, he teaches and mentors students across disciplines, guiding numerous projects and theses. 📚 His innovative research, backed by major grants, has led to impactful publications in synthesis and catalysis. 🧪 His work fuels advancements in affordable pharmaceutical chemistry and sustainable methodologies.

Publication Profile 

Orcid

Education

Assist. Prof. Dr. Saikat Chaudhuri holds an impressive academic background in organic chemistry. He completed his Ph.D. in Organic Chemistry from IISER Bhopal (2013–2017) under the mentorship of Prof. Alakesh Bisai, focusing on the total syntheses of naturally occurring Clavine alkaloids 🧪. Prior to this, he earned his M.Sc. in Organic Chemistry from Visva Bharati University (2010–2012) 📘 and a B.Sc. (Hons.) in Chemistry from Burdwan University (2007–2010) 🔬. His strong academic foundation laid the groundwork for his research excellence and innovative contributions to synthetic organic chemistry and drug development.

Awards

Assist. Prof. Dr. Saikat Chaudhuri has been recognized with several prestigious honors throughout his academic journey. In 2024, he received the Young Scientist Award from the CRS Society, Vidyasagar University 🌟. Earlier, he was awarded the esteemed Dr. D.S. Kothari Postdoctoral Fellowship (2019–2021) by UGC, Government of India 🧪. During his doctoral research, he was a recipient of both Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF) from UGC-NET (2013–2017) 📚. His early promise was evident when he earned the Swami Vivekananda Merit-cum-Means Scholarship (2011–2012) from the Govt. of West Bengal.

Research Focus 

Assist. Prof. Dr. Saikat Chaudhuri is a rising expert in synthetic organic chemistry and medicinal chemistry. His research focuses on the development of novel synthetic methodologies 🧪 for constructing complex heterocycles, such as indoles, benzazepinoindoles, and spiro compounds 🌱. These molecules show promising biological activity, including antibacterial and antifungal properties 💊🦠. He also explores green chemistry approaches, metal-free catalysis, and the total synthesis of natural products 🌍. His work significantly contributes to drug discovery and design, making him a valuable contributor to pharmaceutical research and sustainable chemistry.

Publication Top Notes

  • Synthesis of Dihydro‐benzazepinoindoles via an Oxidative Pictet–Spengler Reaction
  • A New Homogeneous Catalyst for the Synthesis of 3,3′‐Bis(indolyl)methanes: Collective Synthesis of Arundine, Turbomycin B, Arsindoline A, and Tris(1H‐Indol‐3‐yl)methane*
  • A Transition Metal‐Free Strategy for Dihydrobenzazepinoindole via KI‐Mediated Oxidative Pictet–Spengler Reaction
  • Pentafluorophenol‐Catalyzed Metal‐Free Fischer Indole Synthesis: A Novel Approach to Carbazole Derivatives and Desbromoarborescidine A*
  • Water Mediated Chemoselective Synthesis of Novel Spiro Benzoxazinoindoline and Extended Synthesis of Spiro Benzoxazinoindene Derivatives*
  • A Practical and Metal‐Free Approach Towards Synthesis of Spiro‐Benzazepinoindole Derivatives via Pentafluorophenol Catalyzed Pictet‐Spengler Reaction**
  • Efficient, One‐Pot, Green Syntheses of Analogues of 3,4‐Dihydro‐2H Pyrroles as Potential New Antifungal and Antibacterial Agents.
  • A convenient proline catalysed Paal–Knorr synthesis of highly substituted pyrrole: construction of a pyrrolo[2,1-a]isoquinoline scaffold
  • Syntheses of Novel Spirobenzazepinoindole Derivatives via Lewis‐Acid Catalyzed Pictet‐Spengler Cyclization
  • Self-Healable Hydrogels from Vegetable Oil: Preparation, Mechanism, and Applications
  • A Comprehensive Review of Synthetic Approaches Toward Lamellarin D and its Analogous
  • Catalytic Asymmetric Approach to the Naturally Occurring Clavine Alkaloid, (+)-Lysergine
  • Harnessing leather waste in polymer matrix for sustainable smart <scp>shape‐stable</scp> phase change materials
  • Green synthetic approaches for medium ring-sized heterocycles of biological and pharmaceutical interest

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Xinyi Zheng | Pharmacogenomics | Best Researcher Award

Published on by Top Pharmaceutical

Xinyi Zheng | Pharmacogenomics | Best Researcher Award

Ms. Xinyi Zheng Fudan University, China

Ms. Xinyi eis a dedicated researcher in chemical engineering with a strong focus on sustainable polymer science and green catalysis. She has completed over five research projects and contributed 24 articles in SCI-indexed journals. With a citation index of h‑18, Xinyi’s work has attracted wide scholarly attention. She has published 1 book, holds 2 patents, and has contributed to 2 industry-sponsored projects. An editorial board member and an active collaborator internationally, she is also a member of ACS and the Polymer Society of China. Her pioneering innovations make her a strong nominee for the Best Researcher Award 🏆.

Publication Profile 

Orcid

Education

Ms. Xinyi Zheng is a rising star in the field of chemical engineering, specializing in green chemistry and sustainable materials 🌱. She holds a master’s degree in chemical engineering and is currently pursuing her doctoral research with a focus on polymeric catalysts and eco-friendly synthesis methods 🧬. With hands-on experience in academic and industry labs, she has collaborated on cross-disciplinary projects and published widely in high-impact journals 📚. Her work in developing environmentally benign materials has earned recognition for innovation and academic excellence 🏆. Ms. Zheng continues to inspire through her dedication to scientific advancement.

Research and Innovations

Ms. Xinyi Zheng has demonstrated remarkable research excellence through numerous completed and ongoing projects in the fields of green chemistry and sustainable materials 🌱. Her impressive record includes multiple publications in reputed indexed journals 📖, along with innovative patents either published or under process 🔏. With a growing citation index across databases like Scopus and SCI 📊, her work continues to gain global recognition. Additionally, her involvement in consultancy and industry-sponsored projects reflects a strong practical application of her research 💼. Ms. Zheng’s contributions are both impactful and forward-thinking, driving progress in eco-friendly scientific solutions 💡.

Research Focus

Ms. Xinyi Zheng’s research centers on molecular pharmacogenomics, bioinformatics, and precision medicine in oncology and transplantation science 🧪. Her recent work includes analyzing MAPK gene polymorphisms and their roles in renal clear cell carcinoma prognosis and immune response, employing cutting-edge Mendelian randomization and bioinformatic approaches 💻. Additionally, she explores how genetic variations in MAPK pathways affect liver function post-transplant, particularly in patients treated with tacrolimus. Her interdisciplinary focus bridges pharmacology, genomics, and clinical medicine ⚕️—advancing drug response prediction, personalized therapies, and improved transplant outcomes.

Publication Top Notes

Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization

Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus

Laura Weinstein | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Laura Weinstein | Drug Delivery Systems | Best Researcher Award

Ms. Laura Weinstein, University of Delaware, United States

Ms. Laura Weinstein is an accomplished biomedical engineering student at the University of Delaware 🎓, set to graduate in May 2025 with a stellar GPA of 3.97. With minors in nanoscale materials and chemistry 🧪, she has led impactful research in nanoparticle drug delivery, orthotic device innovation, and immunoengineering. Her work spans labs at Delaware and Vanderbilt 🏥, earning her top honors including the Eugene du Pont Memorial Scholarship and Best Poster Awards 🏆. Passionate about translational medicine, Laura’s dedication to improving healthcare through engineering solutions marks her as a rising star in biomedical research 🌟.

Publication Profile 

Google Scholar

Education

Ms. Laura Weinstein is currently pursuing an Honors Bachelor of Science in Biomedical Engineering at the University of Delaware, with expected graduation in May 2025 📅. She maintains an outstanding GPA of 3.97 🌟 and complements her major with minors in Nanoscale Materials and Chemistry ⚗️. Her coursework spans core sciences and advanced engineering, including Introductory Biology 🧬, General Chemistry 🧪, Physics ⚛️, and Biomedical Experimental Design 📊. She has also delved into Immunoengineering, Cell Engineering 🧫, Nanomaterials, and Nanomedicine 💉. Proficient in Python and MATLAB 💻, Laura combines technical skills with scientific curiosity, preparing her for groundbreaking biomedical research 🔬.

Awards

Ms. Laura Weinstein has received numerous prestigious honors throughout her academic journey. From 2021–2025, she was awarded the esteemed Eugene du Pont Memorial Scholarship 🎓, covering full tuition, housing, meals, and book expenses. In 2024, she earned 1st place for designing a prototype to secure thoracostomy tubes 🩺. She is also a National Cyber Scholar (2022–2024) 💻 and won the Biomedical Engineering Distinguished Sophomore Award in 2023 🧬. That same year, she was recognized by the Delaware Department of Technology and Information 📡. In 2022, she placed 1st in the Ratcliffe Eco Entrepreneurship Innovation Sprint 🌱🚀

Experience

Ms. Laura Weinstein has been actively engaged in cutting-edge research at the University of Delaware’s Day Lab since January 2022 🏛️. Under the mentorship of Dr. Emily Day and PhD candidate Eric Sterin 👩‍🏫, she developed polymeric nanoparticles for biomimetic cargo delivery via cancer cell membranes 🧫. She contributed to refining purification protocols for DiD-fluorescent nanoparticles 💡 and guided fellow undergraduates in research techniques 📘. Her dedication extended beyond semesters, participating in multiple research fellowships and programs including the 2022 CBER Summer Scholars REU, 2023 Winter Fellowship, and 2024–2025 Summer/Winter Fellowships 🧪📊—highlighting her passion for biomedical innovation.

Research Focus

Ms. Laura Weinstein focuses her research in the dynamic field of biomedical nanotechnology and targeted drug delivery 🧪. Her studies explore cell biomimicry, using cancer cell membranes to improve therapeutic delivery for hematological cancers 🧫🩸. She also investigates nanoparticle purification challenges, ensuring enhanced precision in drug transport systems 🎯. Her work integrates principles of nanomedicine, immunoengineering, and materials science to develop innovative approaches in cancer treatment and diagnostics 🧬. Through her publications and lab experience, Laura contributes to advancing next-generation polymeric nanoparticle technologies—blending engineering and biology to revolutionize patient care and medical outcomes 🚀💊.

Publication Top Notes

Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes

Standard purification methods are not sufficient to remove micellular lipophilic dye from polymer nanoparticle solution

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Ms. Golgem Mehmetoglu, European University of Lefke, Cyprus

Ms. Gölgem Mehmetoğlu is a dedicated physiotherapist and academic specializing in Physiotherapy and Rehabilitation. 🎓 She earned her B.Sc. from Eastern Mediterranean University (2011–2015), her M.Sc. from European University of Lefke (2015–2017), and is currently pursuing her Ph.D. at EMU. 🧠 Her research focuses on muscle function, postural stability, and rehabilitation outcomes, with multiple publications in international journals and conference proceedings. 📝 She also teaches core courses such as Kinesiology, Biomechanics, and Manual Therapy Techniques. 👩‍🏫 Her scientific contributions and educational roles make her a valuable candidate for the Best Researcher Award.

Publication Profile

Orcid

Education

Ms. Gölgem Mehmetoğlu is a passionate professional in the field of Physiotherapy and Rehabilitation 🧘‍♀️. She completed her undergraduate studies (2011–2015) at Doğu Akdeniz University 🏛️, laying a strong foundation in clinical practice and patient care. She then pursued her Master’s degree (2015–2017) at Lefke Avrupa University 📘, deepening her knowledge in rehabilitation science. Currently, she is advancing her academic journey through a Ph.D. program at Doğu Akdeniz University (2018–present) 🧪. Her academic path reflects commitment to continuous learning and specialization in physiotherapy, contributing to healthcare with evidence-based practice and innovative research.

Academic Positions

Ms. Golgem Mehmetoğlu 🎓 is a dedicated academic in the field of physiotherapy and rehabilitation, actively engaged in teaching at the undergraduate level. She shares her expertise through a variety of core courses including Kinesiology 🤸‍♀️, Biomechanics 🦴, Normal Motor Development 🧠, and Manual Therapy Techniques (Manipulation-Mobilization I & II) 💆‍♀️. Her teaching approach combines theoretical knowledge with hands-on application, empowering students with essential clinical and analytical skills. Through her passionate involvement in education, Ms. Mehmetoğlu continues to inspire future healthcare professionals and contribute meaningfully to the advancement of physiotherapy science.

Research Focus

Ms. Gölgem Mehmetoğlu’s 🔬 research primarily focuses on musculoskeletal rehabilitation, particularly addressing chronic pain, posture correction, functional mobility, and manual therapy in physiotherapy patients. Her studies emphasize the impact of stabilization exercises 🧘‍♀️ on pain relief, posture (craniovertebral angle 📐), disability reduction, and quality of life 🌿 in conditions like chronic neck pain and lateral epicondylitis. Her work explores the integration of exercise science, biomechanics 🤸, and evidence-based physiotherapy to improve patient outcomes. Through randomized controlled trials and clinical interventions, she contributes valuable knowledge to rehabilitation sciences and therapeutic exercise interventions.

Publication Top Notes

Effect of Postural Stabilization Exercises in Combination with Cervical Stabilization Exercises on Craniovertebral Angle, Pain, Disability, and Quality of Life in Patients with Chronic Neck Pain: A Randomized Controlled Trial

The Effects of Muscle Strength and Muscle Endurance on Upper Extremity Functions of Lateral Epicondylitis Patients

The Pain in the Canon of Medicine: Types, Causes, and Treatment

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Dr. Natalia Marina CARDILLO, USDA-ARS-WSU, United States

Dr. Natalia Marina Cardillo is a distinguished veterinary scientist from Argentina with a Ph.D. in Veterinary Sciences, specializing in parasitology and public health 🧫. Currently a Postdoctoral Research Associate at Washington State University 🇺🇸, she focuses on chemotherapeutic strategies for bovine babesiosis. With over two decades of academic and research excellence across UBA, CONICET, INTA, and USDA, she has led groundbreaking projects on zoonoses, antiparasitic drug resistance, and diagnostics. 🧬 Her contributions span teaching, diagnostics, and pharmaceutical clinical trials in veterinary medicine, earning her global recognition and prestigious fellowships.

Publication Profile

Google Scholar

Education

Dr. Natalia Marina Cardillo began her academic path with a Doctor of Veterinary Medicine degree (1997–2004) from the Universidad de Buenos Aires, Argentina, specializing in Public Health 🐕‍🦺🩺. She furthered her expertise by completing a Ph.D. in Veterinary Sciences with a focus on Parasitology and Public Health (2006–2012), earning the prestigious “summa cum laude” distinction for her thesis on Toxocara cati in murine models 🧬🧫. To complement her academic and research proficiency, she pursued a University Teaching Major in Veterinary and Biological Sciences (2014–2016), strengthening her role as an educator and mentor 📚👩‍🏫.

Experience

Dr. Natalia Marina Cardillo has led a distinguished career in parasitology, veterinary microbiology, and public health. Currently a Postdoctoral Research Associate at Washington State University 🐄💊, she focuses on developing novel treatments for bovine babesiosis. Previously, she served as Senior and Principal Scientist at CONICET-INTA 🇦🇷, leading studies on zoonotic parasitic diseases. With over two decades of academic roles at the Universidad de Buenos Aires 👩‍🏫🧫, she also contributed significantly to diagnostics, laboratory accreditation, and veterinary clinical trials. As founder of ALIANZA InVet 🧬🐕, she has pioneered ethical animal research and advanced pharmaceutical testing across Argentina.

Awards

Dr. Natalia Marina Cardillo has received numerous prestigious honors throughout her career. From 2023 to 2025, she was awarded a competitive Postdoctoral Fellowship by the USDA at Washington State University 🇺🇸🔬. In 2018, she won the NAVES entrepreneurship competition by Universidad Austral’s IAE Business School for her CRO-VET project 🏅💼. Her academic excellence was recognized early with a Ph.D. fellowship (2005–2010) in Public Health Veterinary Medicine and a Scientific Research Scholarship (2000–2002) in Parasitology at Universidad de Buenos Aires 🇦🇷📘—highlighting her dedication to veterinary science and innovation.

Research Focus

Dr. Natalia Marina Cardillo’s research is rooted in veterinary parasitology, with a strong emphasis on zoonotic diseases, public health, and epidemiology 🐛🧫🌍. Her work investigates parasites like Toxocara cati, Trichinella spp., and Aelurostrongylus abstrusus, exploring their life cycles, transmission, and pathology in animal hosts and their public health implications 💉📊. She also focuses on developing chemotherapeutic treatments for diseases such as bovine babesiosis, integrating pharmacology, immunology, and molecular diagnostics 🧬💊. Her interdisciplinary research contributes significantly to One Health, bridging human, animal, and environmental health.

Publication Top Notes

Prevalence of Toxocara cati and other parasites in cats’ faeces collected from the open spaces of public institutions: Buenos Aires, Argentina

Trichinella infection in wild animals from endemic regions of Argentina

Experimental Infection with Toxocara cati in BALB/c Mice, Migratory Behaviour and Pathological Changes

Prevalence of canine dirofilariosis in the city of Buenos Aires and its outskirts (Argentina)

Evaluation of the risk of transmission of Trichinella in pork production systems in Argentina

First report of Toxocara cati in the domestic land snail Rumina decollata

Soil contamination with eggs of Toxocara species in public parks of Karaj, Iran

Clinical, haematological, biochemical and economic impacts of Trichinella spiralis infection in pigs

First report of Aelurostrongylus abstrusus in domestic land snail Rumina decollata, in the Autonomous city of Buenos Aires

EXPERIMENTAL INFECTION WITH Toxocara cati IN PIGS: MIGRATORY PATTERN AND PATHOLOGICAL RESPONSE IN EARLY PHASE

Nuevos aportes al conocimiento de Trichinella y trichinellosis

Jian Shi | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs